Reports preliminary Crysvita revenue of $325M-$330M and Dojolvi revenue of $70M-$71M. Sees 2024 revenue guidance between $500M-$530M, consensus $523.86M. 2024 Crysvita revenue expected to be between $375M-$400M, and Dojolvi revenue between $75M-$80M. Sees year-end 2023 cash balance of approximately $776M and 2024 guidance for net cash used in operations expected to be less than $400M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RARE:
- Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones
- Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)
- Ultragenyx receives positive recommendation from NICE in U.K. for Evkeeza
- Ultragenyx announces completion of enrollment in Phase 1/2 trial of GTX-102
- Ultragenyx Announces Completion of Enrollment in Global Phase 1/2 Trial of GTX-102 in Pediatric Patients with Angelman Syndrome
